Literature DB >> 10737486

Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens.

T A Stamey1, C M Yemoto, J E McNeal, B M Sigal, I M Johnstone.   

Abstract

PURPOSE: We determine whether biochemical prostate specific antigen (PSA) failure can be accurately predicted from preoperative serum PSA combined with 6 morphological variables from radical retropubic prostatectomy specimens in men with peripheral zone cancers. The unexpected limitation imposed by preoperative serum PSA on biochemical failure led us to compare peripheral zone to transition zone cancers.
MATERIALS AND METHODS: A total of 326 peripheral zone and 46 transition zone cancers treated only with radical retropubic prostatectomy were followed for a minimum of 3 years (mean and median greater than 5). All prostates were sectioned at 3 mm. intervals and morphological variables were quantitated using the Stanford technique. Biochemical failure was defined as serum PSA 0.07 ng./ml. or greater and increasing. Multivariate logistic regression was used to identify variables with the most independent influence on biochemical failure and derive a clinical equation to predict failure in peripheral zone cancers. The validity of the predictive equation was assessed by out of sample validation and cross validation techniques. The 46 transition zone cancers were compared to the 326 peripheral zone cancers by Student's t and Wilcoxon tests.
RESULTS: Of the peripheral zone failures 60% occurred in the first year after radical retropubic prostatectomy and 95% had occurred by the end of year 4. The highest preoperative serum PSA was 23 ng./ml. among the 181 men biochemically free of disease. Only 15.8% of 57 men with PSA greater than 15 ng./ml. were biochemically disease-free. For the 48 transition zone cancers cure rates were independent of serum PSA with 6 men having PSA greater than 50 ng./ml. Biochemical disease-free status was noted in 80% of transition zone compared to 56% of peripheral zone cancers (p = 0.0009). The most important variables predicting biochemical disease-free status for peripheral zone cancers were percent Gleason grade 4/5, cancer volume, serum PSA and prostate weight. Foci of vascular invasion, intraductal cancer and lymph nodes were less significant variables, and capsular penetration, positive surgical margins and seminal vesical invasion were insignificant. The multivariate logistic equation for predicting failure in peripheral zone cancers was highly accurate and requires only 2 to 3 minutes with a simple calculator.
CONCLUSIONS: Failure of radical retropubic prostatectomy to cure peripheral zone prostate cancer is highly predictable based on 6 morphological variables from the prostatectomy specimen and serum PSA. The level of serum PSA profoundly limits biochemical cure rates in peripheral zone cancers. Transition zone cancers have a high cure rate, despite high serum PSA and adverse morphological variables. Men with serum PSA greater than 15 and perhaps even greater than 10 ng./ml. have such a low cure rate for peripheral zone cancer that re-biopsy attempts appear indicated to prove a transition zone location or else therapy other than radical retropubic prostatectomy should be sought. Pathologists should indicate whether the primary (largest) cancer is in the peripheral or transition zone to prevent overoptimistic reports of cure with radical prostatectomy procedures, as 85% of all tumors are in the peripheral zone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10737486     DOI: 10.1016/s0022-5347(05)67713-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant.

Authors:  Robert J Lechleider; Philip M Arlen; Kwong-Yok Tsang; Seth M Steinberg; Junko Yokokawa; Vittore Cereda; Kevin Camphausen; Jeffrey Schlom; William L Dahut; James L Gulley
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

2.  Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I clinical trial).

Authors:  Maria J Merino; Peter A Pinto; Vanessa Moreno; Sara Gil; Jeffrey Schlom; James L Gulley
Journal:  Hum Pathol       Date:  2018-04-30       Impact factor: 3.466

3.  Anterior tumors of the prostate: diagnosis and significance.

Authors:  Priya N Werahera; E David Crawford; Francisco G La Rosa; Kathleen C Torkko; Beth Schulte; Holly T Sullivan; Adrie van Bokhoven; M Scott Lucia; Fernando J Kim
Journal:  Can J Urol       Date:  2013-10       Impact factor: 1.344

4.  Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading.

Authors:  Lars Egevad; Ferran Algaba; Daniel M Berney; Liliane Boccon-Gibod; Eva Compérat; Andrew J Evans; Rainer Grobholz; Glen Kristiansen; Cord Langner; Gina Lockwood; Antonio Lopez-Beltran; Rodolfo Montironi; Pedro Oliveira; Matthias Schwenkglenks; Ben Vainer; Murali Varma; Vincent Verger; Philippe Camparo
Journal:  Virchows Arch       Date:  2011-06-23       Impact factor: 4.064

5.  Precision of MRI/ultrasound-fusion biopsy in prostate cancer diagnosis: an ex vivo comparison of alternative biopsy techniques on prostate phantoms.

Authors:  N Westhoff; F P Siegel; D Hausmann; M Polednik; J von Hardenberg; M S Michel; M Ritter
Journal:  World J Urol       Date:  2016-11-09       Impact factor: 4.226

6.  Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies : early cancers may contain aggressive genetic features.

Authors:  J C Alers; P J Krijtenburg; A N Vis; R F Hoedemaeker; M F Wildhagen; W C Hop; T T van Der Kwast; F H Schröder; H J Tanke; H van Dekken
Journal:  Am J Pathol       Date:  2001-02       Impact factor: 4.307

7.  The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms.

Authors:  Radka Stoyanova; Niraj H Pahlajani; Brian L Egleston; Mark K Buyyounouski; David Y T Chen; Eric M Horwitz; Alan Pollack
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

Review 8.  Critical review of prostate cancer predictive tools.

Authors:  Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

9.  Intraoperative finding of gross lymph node metastasis during robot-assisted prostatectomy.

Authors:  Wooju Jeong; Shyam Sukumar; Firas Petros; Mani Menon; James O Peabody; Craig G Rogers
Journal:  J Robot Surg       Date:  2011-09-27

10.  Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database.

Authors:  David E Kang; Nicholas J Fitzsimons; Joseph C Presti; Christopher J Kane; Martha K Terris; William J Aronson; Christopher L Amling; Stephen J Freedland
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.